Trial Profile
A Randomized, Open Label, Multicenter, Phase III, 2-Arm Study of Androgen Deprivation With Leuprolide, +/- Docetaxel for Clinically Asymptomatic Prostate Cancer Subjects With a Rising PSA Following Definitive Local Therapy.
Status:
Discontinued
Phase of Trial:
Phase III
Latest Information Update: 10 Nov 2021
Price :
$35
*
At a glance
- Drugs Docetaxel (Primary) ; Bicalutamide; Leuprorelin
- Indications Prostate cancer
- Focus Registrational; Therapeutic Use
- Sponsors Sanofi
- 21 Nov 2012 New source identified and integrated (German Clinical Trials Register; DRKS00004048)
- 01 Sep 2012 Status changed from active, no longer recruiting to discontinued as reported by ClinicalTrials.gov.
- 10 May 2012 Planned end date changed from 1 Oct 2014 to 1 Aug 2012 as reported by ClinicalTrials.gov.